Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,586 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association of PD-L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR-mutated NSCLC.
Hamakawa Y, Agemi Y, Shiba A, Ikeda T, Higashi Y, Aga M, Miyazaki K, Taniguchi Y, Misumi Y, Nakamura Y, Shimokawa T, Saigusa Y, Kobayashi N, Okamoto H, Kaneko T. Hamakawa Y, et al. Among authors: okamoto h. Cancer Med. 2023 Sep;12(17):17788-17797. doi: 10.1002/cam4.6405. Epub 2023 Aug 7. Cancer Med. 2023. PMID: 37548381 Free PMC article.
A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI).
Hida N, Okamoto H, Misumi Y, Sato A, Ishii M, Kashizaki F, Shimokawa T, Shimizu T, Watanabe K. Hida N, et al. Among authors: okamoto h. Cancer Chemother Pharmacol. 2012 Jun;69(6):1625-31. doi: 10.1007/s00280-012-1871-5. Epub 2012 May 8. Cancer Chemother Pharmacol. 2012. PMID: 22565592 Free PMC article. Clinical Trial.
A prospective study of shortened vitamin supplementation prior to cisplatin-pemetrexed therapy for non-small cell lung cancer.
Takagi Y, Hosomi Y, Sunami K, Nakahara Y, Okuma Y, Yomota M, Shimokawa T, Nagamata M, Iguchi M, Okamoto H, Okamura T, Shibuya M. Takagi Y, et al. Among authors: okamoto h. Oncologist. 2014 Nov;19(11):1194-9. doi: 10.1634/theoncologist.2014-0221. Epub 2014 Sep 26. Oncologist. 2014. PMID: 25260366 Free PMC article. Clinical Trial.
A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201).
Eba J, Shimokawa T, Nakamura K, Shibata T, Misumi Y, Okamoto H, Yamamoto N, Ohe Y; Lung Cancer Study Group of the Japan Clinical Oncology Group. Eba J, et al. Among authors: okamoto h. Jpn J Clin Oncol. 2015 Jan;45(1):115-8. doi: 10.1093/jjco/hyu166. Epub 2014 Oct 20. Jpn J Clin Oncol. 2015. PMID: 25332420 Clinical Trial.
A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer.
Tamiya M, Tamiya A, Kaneda H, Nakagawa K, Yoh K, Goto K, Okamoto H, Shimokawa T, Abe T, Tanaka H, Daga H, Takeda K, Hirashima T, Atagi S. Tamiya M, et al. Among authors: okamoto h. Med Oncol. 2016 Jan;33(1):2. doi: 10.1007/s12032-015-0715-7. Epub 2015 Nov 24. Med Oncol. 2016. PMID: 26603297 Clinical Trial.
Multicenter Phase II Study of Nedaplatin and Irinotecan for Patients with Squamous Cell Carcinoma of the Lung: Thoracic Oncology Research Group 0910.
Yamada K, Saito H, Kondo T, Murakami S, Masuda N, Yamamoto M, Igawa S, Katono K, Takiguchi Y, Iwasawa S, Kurimoto R, Okamoto H, Shimokawa T, Hosomi Y, Takagi Y, Kishi K, Ohba M, Oshita F, Watanabe K. Yamada K, et al. Among authors: okamoto h. Anticancer Res. 2015 Dec;35(12):6705-11. Anticancer Res. 2015. PMID: 26637886 Clinical Trial.
Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.
Misumi Y, Okamoto H, Sasaki J, Masuda N, Ishii M, Shimokawa T, Hosomi Y, Okuma Y, Nagamata M, Ogura T, Kato T, Sata M, Otani S, Takakura A, Minato K, Miura Y, Yokoyama T, Takata S, Naoki K, Watanabe K. Misumi Y, et al. Among authors: okamoto h. BMC Cancer. 2017 May 26;17(1):377. doi: 10.1186/s12885-017-3353-y. BMC Cancer. 2017. PMID: 28549414 Free PMC article. Clinical Trial.
Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016.
Ikeda S, Kato T, Ogura T, Sekine A, Oda T, Masuda N, Igawa S, Katono K, Otani S, Yamada K, Saito H, Kondo T, Hosomi Y, Nakahara Y, Nishikawa M, Utumi K, Misumi Y, Yamanaka T, Sakamaki K, Okamoto H. Ikeda S, et al. Among authors: okamoto h. BMC Cancer. 2018 Mar 2;18(1):241. doi: 10.1186/s12885-018-4150-y. BMC Cancer. 2018. PMID: 29499653 Free PMC article. Clinical Trial.
3,586 results